Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435197 | 0.82 | HSD11B1 (0.39) | HSD11B1 | |
| SCHEMBL3428074 | 0.73 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL5244705 | 0.69 | HSD11B1 (0.70) | HSD11B1SIGMAR1ROCK2 | |
| SCHEMBL13674410 | 0.68 | HSD11B1 (0.56) | HSD11B1ROCK2DDB1CRBN | |
| SCHEMBL13435191 | 0.68 | HSD11B1 (1.00) | HSD11B1ROCK2DDB1CRBN | |
| SCHEMBL2986964 | 0.66 | HSD11B1 (1.00) | HSD11B1ROCK2DDB1CRBN | |
| SCHEMBL16390739 | 0.64 | HSD11B1 (0.74) | HSD11B1SIGMAR1ROCK2DDB1CRBN | |
| SCHEMBL6654048 | 0.63 | HSD11B1 (0.56) | HSD11B1SIGMAR1ROCK2DDB1CRBN | |
| SCHEMBL4900366 | 0.63 | HSD11B1 (0.56) | HSD11B1ROCK2DDB1CRBN | |
| SCHEMBL6654051 | 0.63 | HSD11B1 (0.56) | HSD11B1SIGMAR1ROCK2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687644-B2 | Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-30 | — | — | US | disclosed |
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | HSD11B1, HSD11B2, HSDL2 | HSD11B1 1/4885SIGMAR1 1897/4885HTR1A 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.